Intech Investment Management LLC Buys 27,384 Shares of Vaxcyte, Inc. $PCVX

Key Points

• Intech Investment Management LLC increased its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 44.3%, owning 89,212 shares valued at $3,369,000 as of the end of the first quarter.
• Analysts express optimism with a consensus buy rating for Vaxcyte shares, and the average price target is set at $106.25.
• Vaxcyte reported a quarterly loss of ($1.22) EPS, missing expectations, and its stock has seen a 52-week trading range of $27.66 to $121.06.

Intech Investment Management LLC increased its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 44.3% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 89,212 shares of the company's stock after acquiring an additional 27,384 shares during the period. Intech Investment Management LLC owned about 0.07% of Vaxcyte worth $3,369,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its position in Vaxcyte by 10.9% in the first quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company's stock valued at $112,000 after buying an additional 293 shares in the last quarter. Avior Wealth Management LLC lifted its holdings in Vaxcyte by 5.3% in the first quarter. Avior Wealth Management LLC now owns 6,799 shares of the company's stock valued at $257,000 after buying an additional 343 shares during the period. US Bancorp DE lifted its holdings in Vaxcyte by 7.2% in the first quarter. US Bancorp DE now owns 5,344 shares of the company's stock valued at $202,000 after buying an additional 357 shares during the period. Xponance Inc. lifted its holdings in Vaxcyte by 4.7% in the first quarter. Xponance Inc. now owns 9,320 shares of the company's stock valued at $352,000 after buying an additional 415 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Vaxcyte by 1.5% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,635 shares of the company's stock valued at $1,119,000 after purchasing an additional 436 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have commented on PCVX. The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a research note on Friday. They issued a "neutral" rating and a $38.00 target price for the company. Cowen reiterated a "buy" rating on shares of Vaxcyte in a report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $106.25.

Vaxcyte Price Performance

PCVX stock traded down $1.17 during trading hours on Monday, reaching $31.00. The stock had a trading volume of 1,260,839 shares, compared to its average volume of 1,422,392. The stock has a market capitalization of $4.02 billion, a PE ratio of -7.54 and a beta of 1.04. The stock has a 50-day simple moving average of $33.14 and a 200 day simple moving average of $38.47. Vaxcyte, Inc. has a fifty-two week low of $27.66 and a fifty-two week high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same quarter in the previous year, the business posted ($1.10) EPS. On average, sell-side analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.